First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations.
Br J Cancer
; 125(2): 152-154, 2021 07.
Article
en En
| MEDLINE
| ID: mdl-33772155
ABSTRACT
We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx).
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Vacunas contra el Cáncer
/
Neoplasias Pulmonares
Límite:
Humans
País/Región como asunto:
Oceania
Idioma:
En
Año:
2021
Tipo del documento:
Article